Cargando…
Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance
Drug resistance to tyrosine kinase inhibitor (TKI) is the main obstacle for efficient treatment of epidermal growth factor receptor (EGFR)-mutant lung cancer patients. Here we design a cetuximab-capped mesoporous silica nanoparticle (MP-SiO(2) NP) as the drug carrier to specifically target EGFR-muta...
Autores principales: | Wang, Yuetong, Huang, Hsin-Yi, Yang, Liu, Zhang, Zhanxia, Ji, Hongbin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858690/ https://www.ncbi.nlm.nih.gov/pubmed/27151505 http://dx.doi.org/10.1038/srep25468 |
Ejemplares similares
-
Dendritic Mesoporous Silica Hollow Spheres for Nano-Bioreactor Application
por: Zhang, Qian, et al.
Publicado: (2022) -
Overcoming the non-kinetic activity of EGFR1 using multi-functionalized mesoporous silica nanocarrier for in vitro delivery of siRNA
por: Parnian, Javad, et al.
Publicado: (2022) -
The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance
por: Sickmier, E. Allen, et al.
Publicado: (2016) -
Mesoporous Nano-Silica Serves as the Degradation Inhibitor in Polymer Dielectrics
por: Yang, Yang, et al.
Publicado: (2016) -
Nano-Composite Filler of Heteropolyacid-Imidazole Modified Mesoporous Silica for High Temperature PEMFC at Low Humidity
por: Lee, Gicheon, et al.
Publicado: (2022)